Literature DB >> 1972166

IL-6 is an accessory signal in the alternative CD2-mediated pathway of T cell activation.

K Lorré1, J Van Damme, J Verwilghen, M L Baroja, J L Ceuppens.   

Abstract

Recent studies have demonstrated that IL-1 and IL-6 are synergistic accessory signals for activation of T cells. In this study, highly purified human T cells were cultured with either a stimulating pair of anti-CD2 mAb or with immobilized anti-CD3 mAb. Monocytes, a cellfree monocyte culture supernatant or IL-1 were required for anti-CD2-stimulated T cell proliferation, and they each strongly enhanced anti-CD3-induced T cell growth. IL-6 was synergistic with IL-1 as a helper factor for T cell growth after activation via CD2, but we could not demonstrate any effect of IL-6 in the CD3 pathway. The mechanism of the synergistic helper activity of IL-1 and IL-6 on T cell activation in the CD2 pathway was further examined. IL-1 (but not IL-6) was required for induction of IL-2 production. Both IL-1 and IL-6 enhanced IL-2R (p55) expression and the proliferative response to IL-2. T cell proliferation after stimulation with anti-CD2 and IL-1 or IL-1/IL-6 proceeded through an autocrine IL-2-dependent pathway. Moreover we found that, in the absence of IL-1, IL-6 still supported a transient and limited proliferation of anti-CD2- (but not of anti-CD3-) stimulated T cells, which apparently was independent of the autocrine growth factors IL-2 or IL-4. Our data suggest that IL-6 is important as an accessory signal for T cell growth in the CD2 pathway of T cell activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972166

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  The role of adhesion molecules in endothelial cell accessory function.

Authors:  J R Westphal; R M de Waal
Journal:  Mol Biol Rep       Date:  1992-11       Impact factor: 2.316

2.  IL-6 enhances the generation of cytolytic T lymphocytes in the allogeneic mixed leucocyte reaction.

Authors:  J E Ming; R M Steinman; A Granelli-Piperno
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

3.  Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine.

Authors:  I S Leal; B Smedegârd; P Andersen; R Appelberg
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta.

Authors:  M Kruger; S Van Gool; X H Peng; L Coorevits; M Casteels-Van Daele; J L Ceuppens
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

Review 5.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

6.  Interaction of IL-1 beta, IL-6 and tumour necrosis factor-alpha (TNF-alpha) in human T cells activated by murine antigens.

Authors:  S Panzer; M Madden; K Matsuki
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

7.  Signal-dependent pleiotropic regulation of lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3: potent modulation of the hormonal effects by phorbol esters.

Authors:  F G Hustmyer; G Girasole; S C Manolagas
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

8.  Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice.

Authors:  R Appelberg; A G Castro; J Pedrosa; P Minóprio
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

9.  Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.

Authors:  X Cao; W Zhang; S Gu; Y Yu; Q Tao; T Ye
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Increased interleukin 6 production by bronchoalveolar lavage cells in patients with active sarcoidosis.

Authors:  J Homolka; J Müller-Quernheim
Journal:  Lung       Date:  1993       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.